Oral Arsenic Trioxide for NPM1-mutated AML
NCT04689815
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
NPMc+ AML
Interventions
DRUG:
Oral Arsenic Trioxide Formulation
Sponsor
The University of Hong Kong